Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study
2007

Early Results of IMRT for Prostate Cancer Treatment

Sample size: 3 publication Evidence: low

Author Information

Author(s): Anurag K Singh, Peter Guion, Nancy Sears-Crouse, Karen Ullman, Sharon Smith, Paul S Albert, Gabor Fichtinger, Peter L Choyke, Sheng Xu, Jochen Kruecker, Bradford J Wood, Axel Krieger, Holly Ning

Primary Institution: National Cancer Institute

Hypothesis

Can IMRT-based dose escalation effectively target dominant intra-prostatic lesions visible on MRI?

Conclusion

The study shows that IMRT can effectively target and treat dominant intra-prostatic lesions with manageable toxicity.

Supporting Evidence

  • All four intra-prostatic lesions were successfully targeted and treated to 94.5 Gy.
  • Two patients experienced acute RTOG grade 2 genitourinary toxicity, which resolved by 3 months.
  • One patient had no acute toxicity.

Takeaway

Doctors used a special type of radiation therapy to treat cancer spots in the prostate, and it worked well without causing too many side effects.

Methodology

Patients with localized prostate cancer underwent MRI-guided biopsies and received targeted radiation therapy based on MRI findings.

Potential Biases

Potential bias in patient selection and MRI interpretation.

Limitations

The study had a small sample size and short follow-up duration.

Participant Demographics

Three male patients with localized prostate cancer.

Digital Object Identifier (DOI)

10.1186/1748-717X-2-36

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication